Setmelanotide
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Rhythm · Phase 2 · Completed · Enrollment 213
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 16p11.2 Cohort | 9 participants | 1 participants | 1 participants | n/r | 0 |
| AS Cohort | 1 participants | 0 participants | 0 participants | n/r | 0 |
| BBS Cohort | 3 participants | 2 participants | 2 participants | n/r | 0 |
| MC4R Cohort | 12 participants | 7 participants | 7 participants | n/r | 1 |
| POMC/PCSK1/LEPR Heterozygous Cohort | 14 participants | 4 participants | 3 participants | n/r | 0 |
| POMC/PCSK1/LEPR Composite Heterozygous Cohort | 4 participants | 2 participants | 0 participants | n/r | 0 |
| POMC/PCSK1/LEPR Compound Heterozygous Cohort | 13 participants | 6 participants | 1 participants | n/r | 0 |
| SH2B1 Cohort | 13 participants | 6 participants | 4 participants | n/r | 0 |
| SMS Cohort | 2 participants | 0 participants | 4 participants | n/r | 0 |
| SRC1 Cohort | 11 participants | 4 participants | 1 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.